Johnson & Johnson Q2 Delivers Strong Results, Revenue and Profit Both Beat Expectations and Raises Guidance, Pre-Market Stock Price Falls Against Trend

TradingKey - On Wednesday local time, global healthcare giant Johnson & Johnson ( JNJ) reported second-quarter 2026 financial results, with both revenue and earnings beating market expectations. At the same time, management further raised its full-year guidance, once again demonstrating its robust growth capabilities in its two major business segments of Innovative Medicine and MedTech.

However, the company's stock price fell over 2% in premarket trading following the earnings release. Yet, looking at its full-year performance, Johnson & Johnson's stock price still demonstrated strong resilience. Year-to-date, the company's cumulative gain stands at approximately 22%, significantly outperforming the S&P Global 100 Index's gain of about 9.4% over the same period.

Source: TradingView

Revenue and Profit Both Beat Market Expectations

Looking at this quarter's results, Johnson & Johnson maintained its steady growth momentum. The company reported second-quarter revenue of $25.31 billion, higher than the market consensus estimate of $25.02 billion and up approximately 6.6% from $23.74 billion in the same period last year; adjusted earnings per share reached $2.90, also beating analysts' expectations of $2.86.

Following the better-than-expected second-quarter performance, management also raised its full-year earnings guidance. The company now expects adjusted earnings per share for 2025 to be between $11.60 and $11.75, with a midpoint of approximately $11.68, which is higher than the previous market estimate of $11.58.

Meanwhile, the company expects full-year revenue to range between $100.8 billion and $101.4 billion, with a midpoint of approximately $101.1 billion, which is also slightly above the market consensus, indicating that management remains optimistic about its operating performance over the next few quarters.

Joaquin Duato, Chairman and CEO of Johnson & Johnson, stated that the company's second-quarter performance reflects the continuous translation of innovative R&D into commercial outcomes. A diversified product portfolio and a steadily advancing R&D pipeline provide a solid foundation for future growth. The company will continue to advance the development of innovative therapies in major disease areas to meet growing global healthcare needs.

Innovative Pharmaceuticals Become Core Growth Driver

By business segment, the Innovative Medicine business was the primary driver of growth for Johnson & Johnson this quarter, with global operational sales increasing 6.8%.

Among these, DARZALEX, CARVYKTI, TECVAYLI, and RYBREVANT in oncology, TREMFYA in immunology, and SPRAVATO and CAPLYTA in neuroscience all delivered strong performance, becoming the core drivers of growth.

However, declining sales of STELARA and REMICADE dragged down overall growth to some extent, reflecting that the company still faces pressure in navigating the challenges of patent cliffs.

Operational sales in the MedTech business segment grew 3.6%, primarily driven by wound closure products, biosurgery products, electrophysiology products, and the Shockwave business. This growth performance met market expectations and also reflected Johnson & Johnson's continuous innovation capability and market competitiveness in the medical technology sector.

Find out more